206 related articles for article (PubMed ID: 17608776)
1. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
Vorobioff JD; Ferretti SE; Zangroniz P; Gamen M; Picabea E; Bessone FO; Reggiardo V; Diez AR; Tanno M; Cuesta C; Tanno HE
Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
[TBL] [Abstract][Full Text] [Related]
2. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.
Baik SK; Jeong PH; Ji SW; Yoo BS; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ; Lee SS
Am J Gastroenterol; 2005 Mar; 100(3):631-5. PubMed ID: 15743362
[TBL] [Abstract][Full Text] [Related]
3. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
[TBL] [Abstract][Full Text] [Related]
4. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.
Turnes J; Garcia-Pagan JC; Abraldes JG; Hernandez-Guerra M; Dell'Era A; Bosch J
Am J Gastroenterol; 2006 Mar; 101(3):506-12. PubMed ID: 16542287
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
7. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
Baik SK; Park DH; Kim MY; Choi YJ; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ
J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic hemodynamic changes after propranolol in patients with cirrhosis under primary and secondary prophylaxis of variceal bleeding: a pilot study.
de-Madaria E; Palazón JM; Hernández FT; Sánchez-Paya J; Zapater P; Irurzun J; de España F; Pascual S; Such J; Sempere L; Carnicer F; García-Herola A; Valverde J; Pérez-Mateo M
Eur J Gastroenterol Hepatol; 2010 May; 22(5):507-12. PubMed ID: 20150817
[TBL] [Abstract][Full Text] [Related]
11. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
[TBL] [Abstract][Full Text] [Related]
12. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
[TBL] [Abstract][Full Text] [Related]
13. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
14. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis.
Albillos A; Bañares R; González M; Ripoll C; Gonzalez R; Catalina MV; Molinero LM
Am J Gastroenterol; 2007 May; 102(5):1116-26. PubMed ID: 17391317
[TBL] [Abstract][Full Text] [Related]
15. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial.
Vorobioff JD; Gamen M; Kravetz D; Picabea E; Villavicencio R; Bordato J; Ruf A; Bessone F; Romero G; Palazzi J; Nicora A; Passamonti M; Tanno H
Gastroenterology; 2002 Apr; 122(4):916-22. PubMed ID: 11910343
[TBL] [Abstract][Full Text] [Related]
17. Carvedilol or propranolol in portal hypertension? A randomized comparison.
Hobolth L; Møller S; Grønbæk H; Roelsgaard K; Bendtsen F; Feldager Hansen E
Scand J Gastroenterol; 2012 Apr; 47(4):467-74. PubMed ID: 22401315
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term administration of octreotide in portal vein-stenosed rats.
Lin HC; Yang MC; Hou MC; Li SM; Huang YT; Yu PC; Tsai YT; Lee SD
Hepatology; 1996 Mar; 23(3):537-43. PubMed ID: 8617434
[TBL] [Abstract][Full Text] [Related]
19. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis.
Bandi JC; García-Pagán JC; Escorsell A; François E; Moitinho E; Rodés J; Bosch J
Hepatology; 1998 Sep; 28(3):677-82. PubMed ID: 9731558
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A
J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
